Therapeutic protein replacement has demonstrated preclinical and clinical efficacy in neurological disorders but has not been used clinically for Fragile X syndrome (FXS), a genetic neurodevelopmental disorder caused by loss of Fragile X messenger ribonucleoprotein (FMRP). The gene discussed is FMR1; the disease is nervous system disorder.